: Benralizumab improves outcomes in severe eosinophilic asthma patients regardless of smoking history, with former smokers achieving similar benefits in exacerbation reduction, oral corticosteroid sparing, asthma control and lung function to never-smokers https://bit.ly/4grFy7e.
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study
Brussino, Luisa;
2026-01-01
Abstract
: Benralizumab improves outcomes in severe eosinophilic asthma patients regardless of smoking history, with former smokers achieving similar benefits in exacerbation reduction, oral corticosteroid sparing, asthma control and lung function to never-smokers https://bit.ly/4grFy7e.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers_ a post hoc analysis of the ANANKE study - PubMed.pdf
Accesso riservato
Dimensione
234.97 kB
Formato
Adobe PDF
|
234.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
